"Use of Novel Combination Therapies in the Treatment of Advanced HR+/HER2- Breast Cancer"

Evaluate the updated clinical guidelines for combination therapies in the treatment of HR+/HER2- advanced breast cancer patients
Integrate clinical data regarding the use of CDK 4/6 inhibitors to treat HR+/HER2- advanced breast cancer, including appropriate subpopulations
Mitigate toxicities associated with multi-drug treatment regimens to improve patient outcomes
Recognize potential drug-drug interactions to plan effective and safe treatment regimens for each patient

Thursday, November 15 at 12:00pm to 1:00pm

Fred and Pamela Buffett Cancer Center, 5.12.331 505 S 45th St, Omaha, NE 68106

Event Type

Grand Rounds & Seminars

Audience

Students, Faculty and Staff

College/Department

Internal Medicine

Website

https://unmc.zoom.us/j/194142293

Subscribe
Google Calendar iCal Outlook

Recent Activity